Octave Announces Publication of Analytical Validation Study Results in Nature Communications More

Our Science

Powerful innovation to transform MS

We're committed to rigorous and ongoing evaluation.

Browse our latest publications below.

Comparing Neuroradiologist Qualitative Rating of Atrophy to Normative Brain Volume Measures

Improving Patient Outcomes Through a Comprehensive Care Platform in MOVING-MS: A Case Study

Novel Visualization of the Topographical Model of Multiple Sclerosis Using 3D Rendering of Quantified MRI

Predictive Utility of Serum Protein Biomarkers from the Octave MSDA Panel for Optic Neuritis Events in People with Multiple Sclerosis

Improving Patient Outcomes Through a Comprehensive Care Platform in MOVING-MS – A Case Study

Measuring Outcomes and Value: an Integrated, Novel Solution for Generating insights in MS (MOVING MS)

Safety and Effectiveness of Cladribine Tablets After Treatment With Natalizumab (CLADRINA) Trial – Interim Analysis

Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population

Evaluating the Impact of Manual Editing on Automated MRI Lesion Segmentation in Multiple Sclerosis

Discrepancies in the Detection of Salient MS Lesion Counts Between Neuroradiologists and Manually Corrected Automated Lesion Segmentation

1 2 9

Comparing Neuroradiologist Qualitative Rating of Atrophy to Normative Brain Volume Measures

Improving Patient Outcomes Through a Comprehensive Care Platform in MOVING-MS: A Case Study

Novel Visualization of the Topographical Model of Multiple Sclerosis Using 3D Rendering of Quantified MRI

Predictive Utility of Serum Protein Biomarkers from the Octave MSDA Panel for Optic Neuritis Events in People with Multiple Sclerosis

Improving Patient Outcomes Through a Comprehensive Care Platform in MOVING-MS – A Case Study

Measuring Outcomes and Value: an Integrated, Novel Solution for Generating insights in MS (MOVING MS)

Safety and Effectiveness of Cladribine Tablets After Treatment With Natalizumab (CLADRINA) Trial – Interim Analysis

Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population

Evaluating the Impact of Manual Editing on Automated MRI Lesion Segmentation in Multiple Sclerosis

Discrepancies in the Detection of Salient MS Lesion Counts Between Neuroradiologists and Manually Corrected Automated Lesion Segmentation